Gross Profit Analysis: Comparing Regeneron Pharmaceuticals, Inc. and Vericel Corporation

Biotech Giants: Regeneron vs. Vericel Gross Profit Trends

__timestampRegeneron Pharmaceuticals, Inc.Vericel Corporation
Wednesday, January 1, 2014261453900011503000
Thursday, January 1, 2015371101900024698000
Friday, January 1, 2016456073300026076000
Sunday, January 1, 2017547516600033570000
Monday, January 1, 2018627670000058697000
Tuesday, January 1, 2019708120000080279000
Wednesday, January 1, 2020737720000084228000
Friday, January 1, 202113634200000106025000
Saturday, January 1, 202210612500000109788000
Sunday, January 1, 202311301400000135576000
Monday, January 1, 202412231500000
Loading chart...

Unlocking the unknown

Gross Profit Growth: A Tale of Two Biotech Companies

In the dynamic world of biotechnology, financial performance can vary significantly. This analysis compares the gross profit trends of Regeneron Pharmaceuticals, Inc. and Vericel Corporation from 2014 to 2023. Regeneron, a leader in the biotech industry, has seen its gross profit soar by over 330% during this period, peaking in 2021 with a remarkable 13.6 billion dollars. In contrast, Vericel, a smaller player, has experienced a more modest growth of approximately 1,080%, reaching a gross profit of 135.6 million dollars in 2023. This stark difference highlights the diverse scales and growth trajectories within the biotech sector. While Regeneron capitalizes on its established market presence, Vericel's growth, though smaller in absolute terms, reflects its potential in niche markets. This comparison underscores the varied opportunities and challenges faced by companies in the ever-evolving biotech landscape.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025